| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 03/16/1993 | US5194586 Adult T Cell Leukemia Associated Antigen |
| 03/16/1993 | US5194585 Vasoactive peptides |
| 03/16/1993 | US5194426 Method for nerve growth induction |
| 03/16/1993 | US5194424 C63 -amide derivatives of 34-de(acetylglucosaminyl)-34-deoxy-teicoplanin and their use as medicaments against bacteria resistant to glycopeptide antibiotics |
| 03/16/1993 | US5194377 Antibiotic agent |
| 03/16/1993 | US5194375 Dna encoding interleukin-7 receptors and methods of use |
| 03/16/1993 | US5194255 Hypotensive agents from milk |
| 03/16/1993 | US5194245 By comparing the level of oligoadenylate synthetase in an infected and healthy individual |
| 03/16/1993 | CA1314656C Analogs of gonadoliberin with improved solubility, methods for their preparation, agents containing them and their use |
| 03/16/1993 | CA1314655C Hydroxylamine derivatives |
| 03/16/1993 | CA1314481C Liposomal preparation and antibiotic |
| 03/14/1993 | CA2051350A1 Micro-organism and proteases therefrom |
| 03/13/1993 | CA2077948A1 Further novel 5-amino-4-hydroxyhexanoic acid derivatives as therapeutic agents |
| 03/11/1993 | DE4129533A1 Mutierter wachstumsfaktorrezeptor als arzneimittel und seine verwendung zur behandlung von krebs A mutant growth factor receptor as a medicament and its use for treatment of cancer |
| 03/10/1993 | EP0531257A1 Method and device for storing and administering peptid containing dispersions |
| 03/10/1993 | EP0531080A2 Peptide inhibitors of human papilloma virus protein binding to retinoblastoma gene protein |
| 03/10/1993 | EP0530937A1 Collagen-induced platelet aggregation inhibitor |
| 03/10/1993 | EP0530887A1 Organic nitrates, processes for their preparation and their use in the treatment of cardiovascular diseases |
| 03/10/1993 | EP0530804A1 Kits and compositions for the treatment and repair of defects or lesions in cartilage or bone |
| 03/10/1993 | EP0530505A2 Hydantoin derivatives |
| 03/10/1993 | EP0530265A1 Dna encoding human 5-ht 1d? receptors and uses thereof |
| 03/10/1993 | EP0530216A1 Administration of monoclonal antibodies against respiratory viruses |
| 03/10/1993 | EP0417191B1 Formulation for antibody reagents |
| 03/10/1993 | EP0382772B1 Reduction of low density lipoproteins in biological fluids |
| 03/10/1993 | EP0346460B1 Purine derivatives having pharmacological action |
| 03/10/1993 | EP0341302B1 Methods for prevention and treatment of mucositis with granulocyte colony stimulating factor |
| 03/10/1993 | EP0276328B1 Process for separating single-strand human tpa and double-strand human tpa from each other |
| 03/10/1993 | EP0233289B1 Hybridomas producing anti-pseudomonas aeruginosa human monoclonal antibody |
| 03/10/1993 | CN1069737A Insulin analogs |
| 03/10/1993 | CN1069736A New isosteric peptides |
| 03/10/1993 | CN1069730A 2-Piperazinone compounds their production and use |
| 03/09/1993 | US5192788 Porphyrin antiviral compositions |
| 03/09/1993 | US5192747 Anticoagulant peptides |
| 03/09/1993 | US5192746 Cyclic cell adhesion modulation compounds |
| 03/09/1993 | US5192745 Cyclic anticoagulant peptides |
| 03/09/1993 | US5192744 Thrombospondin |
| 03/09/1993 | US5192743 Topical gel mixture with glycerol, tissue factor, and cellulose ether |
| 03/09/1993 | US5192742 Antibiotics |
| 03/09/1993 | US5192741 Sustained and controlled release of water insoluble polypeptides |
| 03/09/1993 | US5192740 Compositions and methods for improving cold tolerance in animals and humans |
| 03/09/1993 | US5192665 Method of ophthalmic testing |
| 03/09/1993 | US5192577 Nutritional composition and a process for its production |
| 03/09/1993 | US5192538 Stable forms of antigenic Taenia ovis polypeptides |
| 03/09/1993 | US5192537 Method of treating renal cell carcinoma using activated mononuclear cells, renal tumor antigen and cimetidine |
| 03/09/1993 | US5192264 Methods and apparatus for treating disease states using oxidized lipoproteins |
| 03/09/1993 | CA1314232C Amino acid composition for parenteral nutritional support |
| 03/09/1993 | CA1314229C Treatment of lipoprotein disorders associated with cholesterol metabolism |
| 03/09/1993 | CA1314217C Microgranular preparation useful in the delivery of biologically active materials to the intestinal regions of animals |
| 03/09/1993 | CA1314211C Agent for reducing nephrotoxicity caused by cyclosporin administration |
| 03/05/1993 | CA2077322A1 Peptide inhibitors of human papilloma virus protein binding to retinoblastoma gene proteins |
| 03/04/1993 | WO1993004373A1 Calcium receptor active molecules |
| 03/04/1993 | WO1993004203A1 Screening methods for immunosuppressive agents |
| 03/04/1993 | WO1993004175A1 Osp a proteins of borrelia burgdorferi subgroups, encoding genes and vaccines |
| 03/04/1993 | WO1993004174A1 Ryegrass pollen allergen |
| 03/04/1993 | WO1993004173A1 Immunoglobulin variants for specific fc epsilon receptors |
| 03/04/1993 | WO1993004170A1 Raf protein kinase therapeutics |
| 03/04/1993 | WO1993004167A1 In vivo gene transfer using implanted retroviral producer cells |
| 03/04/1993 | WO1993004166A1 Purine-region dna binding protein |
| 03/04/1993 | WO1993004164A1 Keratinocyte-derived conditioned medium as a source of growth factors |
| 03/04/1993 | WO1993004086A1 Receptors for advanced glycosylation endproducts and uses thereof |
| 03/04/1993 | WO1993004085A1 Anti-hiv proteins gap 31, dap 30 and dap 32, dna coding therefor and therapeutic uses thereof |
| 03/04/1993 | WO1993004083A1 Human calcium channel compositions and methods |
| 03/04/1993 | WO1993004082A1 Analogs of hirudin |
| 03/04/1993 | WO1993004078A1 Gene encoding mutant l3t4 protein which facilitates hiv infection and transgenic mouse expressing such protein |
| 03/04/1993 | WO1993004043A1 Anti-hiv (aids) agents |
| 03/04/1993 | WO1993003770A1 Method and compositions for cellular reprogramming |
| 03/04/1993 | WO1993003764A1 Hla-restricted hepatitis b virus ctl epitopes |
| 03/04/1993 | WO1993003762A1 Immunostimulation |
| 03/04/1993 | WO1993003761A1 METHODS AND COMPOSITIONS RELATING TO USEFUL ANTIGENS OF $i(MORAXELLA CATARRHALIS) |
| 03/04/1993 | WO1993003760A1 Sirs vaccine and diagnosis method |
| 03/04/1993 | WO1993003758A1 Production of homogeneous neurotrophic factor |
| 03/04/1993 | WO1993003757A1 Muteins of epidermal growth factor exhibiting enhanced binding at low ph |
| 03/04/1993 | WO1993003756A1 Somatotropin for increasing reproductivite performance in cattle |
| 03/04/1993 | WO1993003755A2 Use of relaxin in cardiovascular therapy and in the treatment of neurodegenerative diseases |
| 03/04/1993 | WO1993003754A1 Protein preparation containing the essential amino acids |
| 03/04/1993 | WO1993003753A1 Peptides for inducing cytotoxic t-lymphocyte responses to hepatitis b virus |
| 03/04/1993 | WO1993003752A1 Decapeptide having dopamine stimulating activity |
| 03/04/1993 | WO1993003751A1 Compositions and methods for the sublingual or buccal administration of therapeutic agents |
| 03/04/1993 | WO1993003749A1 Methods and compositions for modulating g protein action |
| 03/04/1993 | WO1993003748A1 Modulation of blood pressure and inhibition of platelet activation with kininogen fragment |
| 03/04/1993 | WO1993003747A1 STABILIZED IL-1α PHARMACEUTICAL PREPARATION |
| 03/04/1993 | WO1993003746A1 Preparation of medicaments containing the peptidoglycan monomer or its derivatives |
| 03/04/1993 | WO1993003745A1 Method of producing well tolerated drugs containing human proteins for administration by infusion or injection |
| 03/04/1993 | WO1993003744A1 Process for producing preserved medicaments containing human proteins for the purposes of infusion or injection |
| 03/04/1993 | WO1993003738A1 Method for treating vascular obstructions caused by abnormal cells |
| 03/04/1993 | WO1993003729A1 N-substituted phenoxazines for treating multidrug resistant cancer cells |
| 03/04/1993 | WO1993003721A1 Cholecystokinin antagonists useful for treating depression |
| 03/04/1993 | WO1993003709A1 Composition and method for treating cystic fibrosis |
| 03/04/1993 | WO1993003708A1 Pharmaceutical aerosol preparation and its use for treatment and prophylaxis of viral diseases |
| 03/04/1993 | WO1993003707A1 Phosphopeptides for the treatment of dental calculus |
| 03/04/1993 | WO1992018160A3 Method for inhibiting adhesion of white blood cells to endothelial cells |
| 03/04/1993 | DE4236293A1 Use of oxytocin, vasopressin and endorphins - for treatment and prevention of e.g. immunological, neurological and organ diseases and conditions caused by pituitary disorder |
| 03/04/1993 | CA2116359A1 Anti-hiv proteins gap 31, dap 30, and dap 32, dna coding therefor and therapeutic uses thereof |
| 03/04/1993 | CA2115833A1 Purine-region dna binding protein |
| 03/04/1993 | CA2115581A1 Anti-hiv (aids) agents |
| 03/04/1993 | CA2115554A1 Osp a proteins of borrelia burgdorferi subgroups, encoding genes and vaccines |
| 03/04/1993 | CA2115424A1 Immunostimulation |
| 03/04/1993 | CA2115364A1 Composition and method for treating cystic fibrosis |
| 03/04/1993 | CA2115361A1 Method for treating vascular obstructions caused by abnormal cells |
| 03/04/1993 | CA2115270A1 The use of the peptidoglycan monomer (pgm), its n-acyl derivatives, and its metal complexes in the preparation of medicaments for the correction of the immunosuppressive and hepatosuppressive states of the organism |